Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.32 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.32 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.32 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.32 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2317693 | 1.00 | CHRNA7 (0.52) | CHRNA7ALDH1A1PSMB1PSMB8PSMB9 | |
| Hydrochloric Acid SCHEMBL10568351 | 0.98 | CHRNA7 (0.50) | CHRNA7ALDH1A1PSMB1PSMB8PSMB9 | |
| SCHEMBL2086631 | 0.98 | CHRNA7 (0.50) | CHRNA7ALDH1A1PSMB1PSMB8PSMB9 | |
| SCHEMBL4758959 | 0.98 | CHRNA7 (0.50) | CHRNA7ALDH1A1PSMB1PSMB8PSMB9 | |
| SCHEMBL4757799 | 0.98 | CHRNA7 (0.50) | CHRNA7ALDH1A1PSMB1PSMB8PSMB9 | |
| Hydrochloric Acid SCHEMBL26112499 | 0.85 | CHRNA7 (0.64) | CHRNA7ALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL9091935 | 0.83 | — | — | |
| SCHEMBL16042687 | 0.81 | CHRNA7 (0.81) | CHRNA7ALDH1A1CHRM2CHRM4CHRM5 | |
| SCHEMBL843660 | 0.72 | — | — | |
| SCHEMBL6099669 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7713977-B2 | Drug for psychological and central nervous system disorders | NOVARTIS AG (CH) | 2010-05-11 | — | — | US | disclosed |
| US-20080262030-A1 | Drug for psychological and central nervous system disorders | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262030-A1 | Drug for psychological and central nervous system disorders | CNR1, CNR2, SLC6A2 | CHRNA7 36/4885ALDH1A1 2084/4885PSMB1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.